Trump’s Drug-Pricing Push to Cut Access Outside US, Study Finds

A study found that the Trump administration's effort to reduce US prescription-drug spending could incentivize pharmaceutical companies to raise prices and restrict patient access in other countries. The policy could shift drug-cost pressures internationally and create regulatory and reputational risks for global pharmaceutical manufacturers.